BIOVAC is one of the leading sterile vaccine manufacturers rooted in Africa, with our core purpose being to "protect life". We are looking to hire a dynamic, passionate, confident, proactive and meticulous Finance Systems Lead to join a goal-oriented team
QUALIFICATIONS NEEDED:
Required:
Preferred:
- Manufacturing / production costing
- Inventory valuation and integration with PP/MM
- Financial integration across end-to-end business processes
KEY DUTIES & RESPONSIBILITIES OF THE ROLE:
Core Technical Delivery:
- General Ledger
- Accounts Payable & Receivable
- Asset Accounting
- Cost Centre Accounting
- Internal Orders
- Profit Centre Accounting
- Product Costing & Cost Object Controlling
- Actual vs Plan variance analysis
- Allocations and month end close processes
- MRP-driven procurement and inventory processes
- Production Planning (PP) and Manufacturing integration
- Sales & Distribution (SD) financial integration
- Product cost planning and cost estimates
- Production order costing and settlements
- Batch costing and variance analysis
- Inventory valuation and Material Ledger / actual costing
- Fit gap analysis and blueprinting
- Business requirements definition and validation
- User Acceptance Testing (UAT)
- Data migration for Finance master and transactional data
- Finance leadership
- Operations, Supply Chain, and Commercial teams
- IT and external implementation partners
- Business planning, budgeting, and forecasting processes
- Management reporting and performance tracking
- KPI definition and adherence
Application Deadline: 06 April 2026
If you do not receive a response from us within three weeks after closing date please understand that your application was not successful.
Disclaimer:
Dear Applicant, we appreciate your interest in joining our organization. It is imperative for us that you understand how we handle your information. We are committed to ensuring the security and confidentiality of the information you provide. Your personal details will be collected for the sole purpose of the application process and will be used strictly for that purpose. By applying, you acknowledge and consent to the collection, use, and protection of your personal information in accordance with our privacy policy. If you have any inquiries or concerns, our Human Capital department is available to provide clarification. We look forward to reviewing your application.''
For detailed information on data handling, please review our privacy notice:
Biovac was founded in 2003 to revive and restore South Africa’s vaccine manufacturing capabilities. We are an African based manufacturer contributing towards filling the gap that exists in the lack of African vaccine manufacturing capability.
We recognise that we’ll only achieve this if we match scientific innovation through local biotechnology skills with the most advanced manufacturing technology and global partnerships. We work closely with local academic institutions, global pharmaceutical companies, the public sector as well as private sector. Some of our achievements are described below:
We manufacture highly advanced vaccines on behalf of leading international biopharmaceutical companies. Biovac is licensed to manufacture a fully liquid hexavalent vaccine from Sanofi that targets and protects against six childhood diseases. In 2021, we envisage to start the manufacture of a multivalent pneumococcal conjugate vaccine from Pfizer.
We supply over 15-million doses of vaccines a year in South Africa and neighbouring countries under strict cold chain conditions.
We have built inhouse product development capability and technologies and have successfully out-licensed one of our technologies to international manufacturers. We are working to establish new safeguards against pathogens like group B streptococcus bacteria, a rising cause of sepsis and meningitis in newborns.
To do this vital work, we rely on sophisticated technology and, above all, the skills and dedication of more than 350 highly trained team members. Along with our partners, we’ve invested over R800 million in infrastructure and skills development at our manufacturing facilities in Cape Town. These investments are resulting in estimated benefits of more than R500-million a year to the national economy.
